Gilead Sciences, Inc. $GILD Shares Bought by Childress Capital Advisors LLC

Childress Capital Advisors LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 68.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,764 shares of the biopharmaceutical company’s stock after purchasing an additional 5,190 shares during the period. Childress Capital Advisors LLC’s holdings in Gilead Sciences were worth $1,417,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Rothschild Investment LLC grew its stake in Gilead Sciences by 1.9% in the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after acquiring an additional 84 shares during the period. Ignite Planners LLC raised its position in Gilead Sciences by 1.1% during the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after acquiring an additional 86 shares during the period. Archer Investment Corp lifted its holdings in Gilead Sciences by 1.2% during the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock valued at $807,000 after purchasing an additional 87 shares in the last quarter. Binnacle Investments Inc grew its position in shares of Gilead Sciences by 14.3% in the second quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company’s stock valued at $78,000 after purchasing an additional 88 shares during the period. Finally, EPG Wealth Management LLC increased its stake in shares of Gilead Sciences by 2.0% during the second quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock worth $513,000 after purchasing an additional 89 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Trading Up 2.6%

Shares of Gilead Sciences stock opened at $121.36 on Wednesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The stock’s 50 day simple moving average is $123.08 and its 200-day simple moving average is $117.34. The stock has a market cap of $150.57 billion, a P/E ratio of 18.82, a P/E/G ratio of 0.63 and a beta of 0.33. Gilead Sciences, Inc. has a 1-year low of $88.57 and a 1-year high of $128.70.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were given a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is presently 48.99%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on GILD shares. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Wells Fargo & Company increased their target price on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Daiwa Capital Markets lifted their price target on Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research note on Thursday, November 13th. Finally, TD Cowen increased their price objective on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $131.68.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $122.00, for a total transaction of $366,000.00. Following the completion of the sale, the chief financial officer directly owned 153,503 shares in the company, valued at approximately $18,727,366. This trade represents a 1.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $124.83, for a total transaction of $1,248,300.00. Following the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at $70,740,911.34. This trade represents a 1.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 136,257 shares of company stock valued at $16,855,192 in the last three months. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.